Fuchs Henry J
- SEC CIK
- 0001197355
No open-market purchases or sales filed in the past year.
Current role at each company
- BMRN Biomarin Pharmaceutical IncPresident, Worldwide R&Das of Sep 17, 2024
- MRTX Mirati Therapeutics, Inc.Directoras of Jan 24, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Fuchs Henry J as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
BMRN Biomarin Pharmaceutical Inc
President, Worldwide R&D2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 7, 2024 (view filing) | Mar 5 | 2 days | Fuchs Henry JPresident, Worldwide R&D | SSale | −35.3K | $85.18 | −$3.01M | −14.3%212.1K after | |
| Aug 11, 2023 (view filing) | Aug 10 | 1 day | Fuchs Henry JPresident, Worldwide R&D | SSale | −12.0K | $90.43 | −$1.09M | −6.4%176.2K after |
MRTX Mirati Therapeutics, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 14, 2022 (view filing) | Feb 11 | 3 days | Fuchs Henry JDirector | SSale | −11.0K | $105.61 | −$1.16M | −64.6%6.02K after | 3 lots |